{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide-semaglutide","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide-semaglutide/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide-semaglutide","title":"Retatrutide and Semaglutide: Evidence on Weight Loss for Reducing Mechanical Load","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:20.958Z","body_excerpt":"## What's breaking down\n\nExcess body weight increases compressive forces on weight-bearing tissues. Each extra pound of body weight adds roughly four pounds of compressive load to the lumbar spine during standing or walking. The same multiplier applies to hips, knees, and plantar fascia. Over time this sustained overload can outpace the tissue's natural repair capacity. Metabolic stress from excess adipose tissue may further impair repair signaling. The result is a cycle where degeneration proceeds faster than regeneration in these structures.\n\nBoth retatrutide and semaglutide are studied primarily for their effects on body weight. Weight reduction lowers the absolute mechanical load placed on these tissues. This addresses one layer of the problem without directly acting on disc cells or cartilage matrix.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nA phase 2 human trial measured body-weight change at 48 weeks. Participants receiving the highest dose reached a mean reduction of 24.2 percent versus 2.1 percent on placebo (human data). Later phase 3 data reported 28.3 percent mean loss at 80 weeks on 12 mg, with further extension to 30.3 percent at 104 weeks in a subset (human data). These reductions translate directly into lower daily compressive forces on the spine and joints.\n\n## Why Semaglutide might help you\n\n1. What keeps failing: Weight-related joint and disc overload; metabolic stress on repair capacity.\n2. What Semaglutide is studied to do: Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\n3. Therefore for you: If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nThe STEP 1 human trial showed a mean 14.9 percent weight reduction at 68 weeks versus 2.4 percent on placebo. Across the STEP program, sustained losses of 12–15 percent were typical at one to two years (human data). Each percentage point lost reduces the absolute load on the lumbar spine by approximately the same proportion.\n\n## How these fit together\n\nEach compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.\n- Retatrutide → metabolic load / body weight\n- Semaglutide → metabolic load / body weight\n\nBoth act through overlapping yet distinct receptor pathways to promote weight loss. Retatrutide adds glucagon receptor activity on top of GLP-1 and GIP agonism, which in trials produced larger average losses than semaglutide alone. The shared outcome remains reduced body mass and therefore lower mechanical stress on weight-sensitive structures. No data show additive effects when both are used together; they are separate options within the same mechanistic category.\n\n## What the evidence actually shows\n\nHuman trials form the core data set. The 2023 NEJM phase 2 retatrutide study enrolled 338 adults and reported dose-dependent weight loss up to 24.2 percent at 48 weeks. The 2026 TRIUMPH-1 phase 3 trial reported 28.3 percent mean loss at 80 weeks. Semaglutide STEP 1 data showed 14.9 percent at 68 weeks. No published head-to-head randomized trials directly compare the two agents in the same population. All weight-loss figures are least-squares means from intention-to-treat analyses. Preclinical rodent studies exist but are not required here because human data are available.\n\n## What scientists say\n\nTrial investigators note that the weight reductions observed with retatrutide approach levels historically seen after bariatric surgery. They emphasize gastroi","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c4","text":"Each pound of body weight lost reduces lumbar compressive force by approximately four pounds.","tier":"mechanistic","weight":0.3,"section":"What's breaking down","slot":null,"interaction_risk":false,"status":"active","source_ids":[],"source_status":"unsourced","why_material":"Explains the mechanical-load logic chain.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c1","text":"Retatrutide phase 2 trial showed up to 24.2% mean weight loss at 48 weeks in humans.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Provides quantified human weight-loss data relevant to mechanical load reduction.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c2","text":"Retatrutide phase 3 TRIUMPH-1 reported 28.3% mean loss at 80 weeks and 30.3% at 104 weeks in humans.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Updates efficacy magnitude for load-reduction discussion.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"Semaglutide STEP 1 trial showed 14.9% mean weight loss at 68 weeks in humans.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Baseline comparator for GLP-1 weight-loss effect.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 human trial results for retatrutide weight loss.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"2c7b97fa37c351829bca01bd9f6427fbe4ae66036f658862ecebb5bc4869fae8"},{"id":"s2","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial","quote":"In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss","summary":"Phase 3 retatrutide weight-loss data released 2026.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"7a3bc5e84b044c3b4238cba3964f99caecc103f0d3cc1bd8f6c5467aa3f8a064"},{"id":"s3","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","quote":"The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo","summary":"STEP 1 human trial results for semaglutide.","claim_ids":["c3"],"link_status":"http_403","quote_status":"unverified","hash":"21bc647acae4f673f50ea597757acea6da7b3b93faf89442a7e52a8efd59cba3"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial","quote":"At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −8.7% in the 1-mg group, −17.1% in the combined 4-mg group, −22.8% in the combined 8-mg group, and −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.","summary":"Phase 2 human trial results for retatrutide weight loss.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"2c7b97fa37c351829bca01bd9f6427fbe4ae66036f658862ecebb5bc4869fae8"},{"id":"s3","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","quote":"The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo","summary":"STEP 1 human trial results for semaglutide.","claim_ids":["c3"],"link_status":"http_403","quote_status":"unverified","hash":"21bc647acae4f673f50ea597757acea6da7b3b93faf89442a7e52a8efd59cba3"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"retatrutide-semaglutide","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":3,"anecdotal":0,"scientific":2,"user_reports":0,"questions":0,"evidence_ingests":0}}